Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (99)	8/20/2001 4:52:19 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 631

Enbrel continues to amaze me. I expected efficacy across a variety of indications. However, I didn't expect dramatic efficacy in any indication.......... ENBREL was generally well tolerated in this study. Side effects seen more frequently within the first 12 weeks of the study in patients receiving ENBREL included mild infections (46 percent compared to 24 percent of placebo patients). The majority of infections were upper respiratory infections similar to colds. Wow. Not too cool.